These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 8783666

  • 1. Use of amifostine in bone marrow purging.
    Cagnoni PJ, Jones RB, Bearman SI, Ross M, Hami L, Franklin WA, Capizzi R, Schein PS, Shpall EJ.
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [Abstract] [Full Text] [Related]

  • 2. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M, Grisanti S, Granzow K, Saladini A, Sala A, Nozza A, Molteni A, Passamonti F, Carlo-Stella C, Santoro A, Siena S.
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [Abstract] [Full Text] [Related]

  • 3. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support.
    Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W.
    Blood; 1994 Jun 01; 83(11):3132-7. PubMed ID: 8193351
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L, Hu C, Giarratana MC, Gorin NC.
    Semin Oncol; 1994 Oct 01; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [Abstract] [Full Text] [Related]

  • 5. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
    Fauth F, Martin H, Sonnhoff S, Bialleck H, Wiesneth M, Mihanovic B, Hoelzer D.
    Bone Marrow Transplant; 2000 Apr 01; 25(8):831-6. PubMed ID: 10808203
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 7. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery.
    Biggs D, Stadtmauer E, Mangan P, Edelstein M, Powlis W, Buzby G, Magee D, Sachs B, Silberstein L.
    Prog Clin Biol Res; 1994 Sep 01; 389():9-15. PubMed ID: 7535466
    [No Abstract] [Full Text] [Related]

  • 8. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dubé I, Hewitt K, Berinstein NL.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide.
    Passos-Coelho J, Ross AA, Davis JM, Huelskamp AM, Clarke B, Noga SJ, Davidson NE, Kennedy MJ.
    Cancer Res; 1994 May 01; 54(9):2366-71. PubMed ID: 8162582
    [Abstract] [Full Text] [Related]

  • 10. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L, Lalle M, Pandolfi A, Ruscio C, Amodeo R.
    Ann Hematol; 2002 Oct 01; 81(10):575-81. PubMed ID: 12424539
    [Abstract] [Full Text] [Related]

  • 11. Effect of Ethiofos on cytotoxicity of pharmacological purging protocols used for autologous marrow grafts in acute lymphoblastic leukemia.
    Skala JP, Rogers PC, Chan KW, Rodriguez WC.
    Prog Clin Biol Res; 1992 Oct 01; 377():57-62. PubMed ID: 1332075
    [No Abstract] [Full Text] [Related]

  • 12. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation.
    Shpall EJ, Stemmer SM, Bearman SI, Myers S, Purdy M, Jones RB.
    Breast Cancer Res Treat; 1993 Oct 01; 26 Suppl():S19-23. PubMed ID: 7691269
    [Abstract] [Full Text] [Related]

  • 13. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement.
    Bird JM, Luger S, Mangan P, Edelstein M, Silberstein L, Powlis W, Ball J, Schultz DJ, Stadtmauer EA.
    Bone Marrow Transplant; 1996 Aug 01; 18(2):309-13. PubMed ID: 8864439
    [Abstract] [Full Text] [Related]

  • 14. Clinical status of the new cytoprotective agent, amifostine.
    Kalaycioglu M, Bukowski R.
    Oncology (Williston Park); 1994 Jul 01; 8(7):15-6, 19-20, 23. PubMed ID: 7522504
    [Abstract] [Full Text] [Related]

  • 15. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 16. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
    Meagher RC, Rothman SA, Paul P, Koberna P, Willmer C, Baucco PA.
    Cancer Res; 1989 Jul 01; 49(13):3637-41. PubMed ID: 2543500
    [Abstract] [Full Text] [Related]

  • 17. Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
    Poloni A, Leoni P, Curzi L, Cantori I, Mancini S, Montanari M, Masia MC, Olivieri A.
    Exp Hematol; 1999 Oct 01; 27(10):1548-56. PubMed ID: 10517497
    [Abstract] [Full Text] [Related]

  • 18. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL, Gorin NC.
    Blood; 1995 Oct 01; 86(7):2849-55. PubMed ID: 7670119
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R, Bony V, Lopez M.
    Prog Clin Biol Res; 1994 Oct 01; 389():23-9. PubMed ID: 7700906
    [No Abstract] [Full Text] [Related]

  • 20. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    J Clin Oncol; 2003 Oct 15; 21(20):3744-53. PubMed ID: 12963703
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.